Alectinib news

All news on Alectinib (also known as Alecensa): plants, production capacities, investments and involved companies.

16 September 2026

Chugai: FoundationOne CDx approved as companion diagnostic for tovorafenib in BRAF‑altered/fusion glioma

Approval allows FoundationOne CDx to detect BRAF V600 alterations and BRAF fusion genes to guide tovorafenib treatment in glioma and expands companion indications to nine cancer types.
18 May 2026

Chugai’s Alecensa Gets World-First Tumor‑Agnostic Approval for ALK‑Positive Solid Tumors

Japan approves tumor‑agnostic ALK inhibitor for ALK‑fusion solid tumors including pediatrics. TACKLE Phase II showed 70–76% response in ALK‑fusion cases; safety consistent. FoundationOne CDx approved.
18 May 2026

Chugai: MHLW approves FoundationOne CDx as Alecensa companion diagnostic for ALK‑positive solid tumors

TACKLE Phase II supported Alecensa's efficacy/safety, enabling a partial marketing-authorization change; FoundationOne CDx expands tumor-agnostic genomic profiling and treatment options.
13 October 2025

Roche Highlights Cancer Treatment Advances at ESMO 2025

Roche presents over 30 abstracts on cancer treatments, including breast, lung, and bladder cancers, at ESMO 2025, showcasing significant advancements in progression-free and overall survival.

Who will be producing Alectinib in the future?

Find out with chemXplore Alpha

Learn more